A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer

Makoto Shinoto, Kotaro Terashima, Hiroaki Suefuji, Akira Matsunobu, Shingo Toyama, Kaori Fukunishi, Yoshiyuki Shioyama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The aim of this study was to evaluate the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for unresectable locally advanced pancreatic cancer (LAPC). Methods and materials: Patients with LAPC treated with definitive C-ion RT between April 2014 and July 2017 were analyzed retrospectively. The prescribed dose was 55.2 Gy (relative biological effectiveness [RBE] weighted absorbed dose) in 12 fractions. Overall survival (OS), local control (LC), progression free survival (PFS), and toxicity were evaluated. Results: Sixty-four patients were enrolled. All patients completed planned course of C-ion RT. The median follow-up time for survivors from the initiation of C-ion RT was 24.4 months (range, 5.1–46.1 months). Median survival time was 25.1 months. Two-year OS, LC, and PFS were 53% (95% confidence interval [CI], 39%–66%), 82% (95% CI, 66%–91%), and 23% (95% CI, 14%–36%), respectively. Four patients experienced acute grade 3 toxicities including 3 gastrointestinal (GI) toxicities. There was no grade 3 or more late toxicity. Conclusions: The clinical results of C-ion RT for LAPC at our institution were comparable to those of a recent multi-institutional analysis.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalRadiotherapy and Oncology
Volume129
Issue number2
DOIs
Publication statusPublished - Nov 2018

Fingerprint

Heavy Ion Radiotherapy
Pancreatic Neoplasms
Drug Therapy
Confidence Intervals
Disease-Free Survival
Survival
Relative Biological Effectiveness
Survivors
Safety

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. / Shinoto, Makoto; Terashima, Kotaro; Suefuji, Hiroaki; Matsunobu, Akira; Toyama, Shingo; Fukunishi, Kaori; Shioyama, Yoshiyuki.

In: Radiotherapy and Oncology, Vol. 129, No. 2, 11.2018, p. 333-339.

Research output: Contribution to journalArticle

Shinoto, Makoto ; Terashima, Kotaro ; Suefuji, Hiroaki ; Matsunobu, Akira ; Toyama, Shingo ; Fukunishi, Kaori ; Shioyama, Yoshiyuki. / A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. In: Radiotherapy and Oncology. 2018 ; Vol. 129, No. 2. pp. 333-339.
@article{579dec94e91c4a28b8e190a123208bef,
title = "A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer",
abstract = "Purpose: The aim of this study was to evaluate the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for unresectable locally advanced pancreatic cancer (LAPC). Methods and materials: Patients with LAPC treated with definitive C-ion RT between April 2014 and July 2017 were analyzed retrospectively. The prescribed dose was 55.2 Gy (relative biological effectiveness [RBE] weighted absorbed dose) in 12 fractions. Overall survival (OS), local control (LC), progression free survival (PFS), and toxicity were evaluated. Results: Sixty-four patients were enrolled. All patients completed planned course of C-ion RT. The median follow-up time for survivors from the initiation of C-ion RT was 24.4 months (range, 5.1–46.1 months). Median survival time was 25.1 months. Two-year OS, LC, and PFS were 53{\%} (95{\%} confidence interval [CI], 39{\%}–66{\%}), 82{\%} (95{\%} CI, 66{\%}–91{\%}), and 23{\%} (95{\%} CI, 14{\%}–36{\%}), respectively. Four patients experienced acute grade 3 toxicities including 3 gastrointestinal (GI) toxicities. There was no grade 3 or more late toxicity. Conclusions: The clinical results of C-ion RT for LAPC at our institution were comparable to those of a recent multi-institutional analysis.",
author = "Makoto Shinoto and Kotaro Terashima and Hiroaki Suefuji and Akira Matsunobu and Shingo Toyama and Kaori Fukunishi and Yoshiyuki Shioyama",
year = "2018",
month = "11",
doi = "10.1016/j.radonc.2018.08.026",
language = "English",
volume = "129",
pages = "333--339",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer

AU - Shinoto, Makoto

AU - Terashima, Kotaro

AU - Suefuji, Hiroaki

AU - Matsunobu, Akira

AU - Toyama, Shingo

AU - Fukunishi, Kaori

AU - Shioyama, Yoshiyuki

PY - 2018/11

Y1 - 2018/11

N2 - Purpose: The aim of this study was to evaluate the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for unresectable locally advanced pancreatic cancer (LAPC). Methods and materials: Patients with LAPC treated with definitive C-ion RT between April 2014 and July 2017 were analyzed retrospectively. The prescribed dose was 55.2 Gy (relative biological effectiveness [RBE] weighted absorbed dose) in 12 fractions. Overall survival (OS), local control (LC), progression free survival (PFS), and toxicity were evaluated. Results: Sixty-four patients were enrolled. All patients completed planned course of C-ion RT. The median follow-up time for survivors from the initiation of C-ion RT was 24.4 months (range, 5.1–46.1 months). Median survival time was 25.1 months. Two-year OS, LC, and PFS were 53% (95% confidence interval [CI], 39%–66%), 82% (95% CI, 66%–91%), and 23% (95% CI, 14%–36%), respectively. Four patients experienced acute grade 3 toxicities including 3 gastrointestinal (GI) toxicities. There was no grade 3 or more late toxicity. Conclusions: The clinical results of C-ion RT for LAPC at our institution were comparable to those of a recent multi-institutional analysis.

AB - Purpose: The aim of this study was to evaluate the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for unresectable locally advanced pancreatic cancer (LAPC). Methods and materials: Patients with LAPC treated with definitive C-ion RT between April 2014 and July 2017 were analyzed retrospectively. The prescribed dose was 55.2 Gy (relative biological effectiveness [RBE] weighted absorbed dose) in 12 fractions. Overall survival (OS), local control (LC), progression free survival (PFS), and toxicity were evaluated. Results: Sixty-four patients were enrolled. All patients completed planned course of C-ion RT. The median follow-up time for survivors from the initiation of C-ion RT was 24.4 months (range, 5.1–46.1 months). Median survival time was 25.1 months. Two-year OS, LC, and PFS were 53% (95% confidence interval [CI], 39%–66%), 82% (95% CI, 66%–91%), and 23% (95% CI, 14%–36%), respectively. Four patients experienced acute grade 3 toxicities including 3 gastrointestinal (GI) toxicities. There was no grade 3 or more late toxicity. Conclusions: The clinical results of C-ion RT for LAPC at our institution were comparable to those of a recent multi-institutional analysis.

UR - http://www.scopus.com/inward/record.url?scp=85053175734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053175734&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2018.08.026

DO - 10.1016/j.radonc.2018.08.026

M3 - Article

C2 - 30224179

AN - SCOPUS:85053175734

VL - 129

SP - 333

EP - 339

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -